Unified Protocol for Transdiagnostic Treatment of Emotional Disorders for Depression

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Pittsburgh, Pittsburgh, PA
Depression+7 More
Unified Protocol for Transdiagnostic Treatment of Emotional Disorders - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Emergency responders protect the public despite occupational hazards that threaten their mental health. The Pitt Center for Emergency Responder Wellness will be a clinical innovation hub that: 1) delivers accessible interventions for promoting mental health and overall wellbeing; 2) trains the next generation of students to provide mental health care for emergency responders; and 3) informs scientific understanding of post-trauma recovery processes. Goals for the seed phase are to establish our team and collect pilot data to demonstrate feasibility and initial clinical impact.

Eligible Conditions

  • Depression
  • Anxiety
  • Post Traumatic Stress Disorder (PTSD)
  • Alcohol Use Disorders (AUD)

Treatment Effectiveness

Study Objectives

8 Primary · 4 Secondary · Reporting Duration: The PHQ-9 will be administered at baseline and follow-up (7 months post-baseline).

Month 7
Change from baseline to follow-up in alcohol misuse severity measured using the Alcohol Use Disorders Identification Test (AUDIT)
Week 20
Change from baseline to post-treatment in alcohol misuse severity measured using the Alcohol Use Disorders Identification Test (AUDIT)
Month 7
Change from baseline to follow-up in anxiety symptom severity measured using the Generalized Anxiety Disorder-7 (GAD-7)
Week 20
Change from baseline to post-treatment in anxiety symptom severity measured using the Generalized Anxiety Disorder-7 (GAD-7)
Month 7
Change from baseline to follow-up in posttraumatic stress disorder (PTSD) symptom severity using the PTSD Checklist for DSM-5 (PCL-5)
Week 20
Change from baseline to post-treatment in posttraumatic stress disorder (PTSD) symptom severity using the PTSD Checklist for DSM-5 (PCL-5)
Month 7
Change from baseline to follow-up in depressive symptoms measured using the Patient Health Questionnaire-9 (PHQ-9)
Week 20
Change from baseline to post-treatment in depressive symptom measured using the Patient Health Questionnaire-9 (PHQ-9)
Month 7
Change from baseline to follow-up in quality of life measured using the World Health Organization Quality of Life (WHOQOL-BREF).
Week 20
Change from baseline to post-treatment in quality of life measured using the World Health Organization Quality of Life (WHOQOL-BREF).
Month 7
Change from baseline to follow-up in functional impairment measured using the Work and Social Adjustment Scale (WSAS)
Week 20
Change from baseline to post-treatment in functional impairment measured using the Work and Social Adjustment Scale (WSAS)

Trial Safety

Trial Design

1 Treatment Group

Transdiagnostic cognitive behavioral therapy
1 of 1
Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders · No Placebo Group · N/A

Transdiagnostic cognitive behavioral therapy
Behavioral
Experimental Group · 1 Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
2020
N/A
~60

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: the phq-9 will be administered at baseline and follow-up (7 months post-baseline).

Trial Background

Prof. Eric Meyer, Professor, Principal Investigator
Principal Investigator
University of Pittsburgh
Closest Location: University of Pittsburgh · Pittsburgh, PA
Photo of University of Pittsburgh Medical Center   1Photo of University of Pittsburgh Medical Center   2Photo of University of Pittsburgh Medical Center  3
2004First Recorded Clinical Trial
29 TrialsResearching Depression
646 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The criterion is met if the respondent has had an emergency response training experience in which they encountered an emergency.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.